Loading clinical trials...
Loading clinical trials...
Multicentre, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab in Patients Suffering From Follicular Non-Hodgkin's Lymphoma (FNHL) With Residual Minimal Disease After Autologous Transplantation of hematopoïetic Stem Cell (Bone Marrow or Peripheral Blood)
Conditions
Interventions
rituximab [MabThera/Rituxan]
Locations
1
France
Toulouse, France
Start Date
November 1, 1998
Primary Completion Date
April 1, 2004
Completion Date
April 1, 2004
Last Updated
November 2, 2016
NCT06667687
NCT05623982
NCT03314974
NCT04586478
NCT05054257
NCT01746849
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions